Published in Infect Immun on March 01, 2001
Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun (2011) 1.41
Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact (2010) 1.23
O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a. Carbohydr Res (2006) 1.04
Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS One (2011) 0.94
Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium. Infect Immun (2014) 0.93
Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines. Bioconjug Chem (2011) 0.90
Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody. Proc Natl Acad Sci U S A (2008) 0.85
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. Hum Vaccin Immunother (2015) 0.84
Increased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering. Open Biol (2015) 0.78
The genome of Shigella dysenteriae strain Sd1617 comparison to representative strains in evaluating pathogenesis. FEMS Microbiol Lett (2015) 0.78
Dipstick test for rapid diagnosis of Shigella dysenteriae 1 in bacterial cultures and its potential use on stool samples. PLoS One (2011) 0.78
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. Clin Vaccine Immunol (2016) 0.77
Expression of Shigella flexneri ipaB Gene in Tobacco. Avicenna J Med Biotechnol (2013) 0.76
Shigella Vaccine Development: Finding the Path of Least Resistance. Clin Vaccine Immunol (2016) 0.75
New method for quantitative determination of uronic acids. Anal Biochem (1973) 27.02
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
A method for the quantitative modification and estimation of carboxylic acid groups in proteins. J Biol Chem (1967) 4.65
Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment. Am J Trop Med Hyg (1955) 3.48
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25
Are diarrhoea control programmes likely to reduce childhood malnutrition? Observations from rural Bangladesh. Lancet (1989) 2.90
Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh. Pediatrics (1984) 2.37
Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol (1991) 2.34
Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis (1972) 2.29
Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis (1988) 2.14
Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 2.10
The role of Shigella spp., enteroinvasive Escherichia coli, and other enteropathogens as causes of childhood dysentery in Thailand. J Infect Dis (1986) 2.06
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Purification and some properties of a Vero toxin from a human strain of Escherichia coli that is immunologically related to Shiga-like toxin II (VT2). Microb Pathog (1989) 1.78
Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol (1991) 1.73
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun (1990) 1.69
Diagnosis and management of dysentery by community health workers. Lancet (1988) 1.64
Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J Clin Microbiol (1989) 1.58
Clinical and microbiologic features of Shigella and enteroinvasive Escherichia coli infections detected by DNA hybridization. J Clin Microbiol (1988) 1.57
Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis (1992) 1.53
The measurement of amino groups in proteins and peptides. Biochem J (1971) 1.51
Failure of parenteral vaccines to protect monkeys against experimental shigellosis. Proc Soc Exp Biol Med (1967) 1.46
Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci U S A (1999) 1.34
Four decades of shigellosis in Israel: epidemiology of a growing public health problem. Rev Infect Dis (1991) 1.26
Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest (1985) 1.25
Succinylation of pepsinogen. J Biol Chem (1967) 1.17
Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect Immun (1996) 1.17
Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis (1999) 1.07
Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J Infect Dis (1998) 1.05
Existing status of shigellosis in Andaman & Nicobar islands. Indian J Med Res (1996) 1.04
Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. J Infect Dis (1988) 1.04
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun (1996) 1.00
Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. J Infect Dis (1991) 0.99
Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infect Immun (1995) 0.97
Dysentery, not watery diarrhoea, is associated with stunting in Bangladeshi children. Hum Nutr Clin Nutr (1987) 0.97
Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun (1998) 0.96
Shigella and enteroinvasive Escherichia coli infections in households of children with dysentery in Bangkok. J Infect Dis (1992) 0.95
Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc Natl Acad Sci U S A (1995) 0.94
Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. Am J Dis Child (1987) 0.93
Single mutation in the A domain of diphtheria toxin results in a protein with altered membrane insertion behavior. Biochim Biophys Acta (1987) 0.90
Shigella lipopolysaccharide antibodies in pediatric populations. Pediatr Infect Dis J (1995) 0.86
Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect Immun (2000) 0.85
Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice. Infect Immun (1999) 0.81
The epidemiology of shigellosis in Israel. Ann Trop Med Parasitol (1988) 0.79
Relationship between humoral immune responses and oral temperature during human shigellosis. J Infect Dis (1993) 0.76
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature (1996) 6.17
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol (1985) 4.88
A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab (1971) 4.38
A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 4.30
Characterization of the imitation switch subfamily of ATP-dependent chromatin-remodeling factors in Saccharomyces cerevisiae. Genes Dev (1999) 4.25
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med (2001) 4.08
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet (1997) 3.68
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25
Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem (1996) 3.05
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol (1985) 2.97
Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem (1996) 2.95
Lipid on capsular polysaccharides of gram-negative bacteria. J Biol Chem (1981) 2.91
Frequency of E. coli K antigens in urinary-tract infections in children. Lancet (1977) 2.89
Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med (1979) 2.89
Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet (1971) 2.84
Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med (1987) 2.83
Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx. Pediatr Res (1975) 2.74
Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis (1990) 2.72
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry (1978) 2.65
Comparative analysis of plasmids and some metabolic characteristics of Escherichia coli K1 from diseased and healthy individuals. Infect Immun (1980) 2.59
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2.59
The isolation and biologic activities of purified secretory IgA and IgG anti-Salmonella typhimurium "O" antibodies from rabbit intestinal fluid and colostrum. J Immunol (1971) 2.54
Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun (1972) 2.47
Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol (1978) 2.44
Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett (1998) 2.40
Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1. Infect Immun (1977) 2.39
Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun (1988) 2.36
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection (1992) 2.35
The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg (2000) 2.29
Differential complement resistance mediates virulence of Haemophilus influenzae type b. Infect Immun (1982) 2.23
Production of monovalent antisera by induction of immunological tolerance for capsular typing of Streptococcus pneumoniae. FEMS Microbiol Lett (1992) 2.19
Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis (1984) 2.17
Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med (1975) 2.16
Gamma-A-immunoglobulin from rabbit colostrum. J Immunol (1966) 2.16
Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet (1994) 2.15
Molecular cloning of the K1 capsular polysaccharide genes of E. coli. Nature (1981) 2.15
Emergency caesarean section in a patient with myotonic dystrophy: a case of failed postoperative extubation in a patient with mild disease. Anaesth Intensive Care (2011) 2.14
Clinical, bacteriological, and immunological characterisation of ampicillin-resistant Haemophilus influenzae type B. Lancet (1974) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 2.10
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis (2000) 2.04
Long-term survival following bacteremia or fungemia. JAMA (1995) 2.03
Urinary tract infection: is there a need for routine renal ultrasonography? Arch Dis Child (2004) 2.00
Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics (1985) 1.98
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol (1994) 1.88
Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnology (N Y) (1994) 1.87
Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis (1977) 1.84
Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J Infect Dis (1989) 1.82
Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun (1986) 1.79
Photosynthetic and photorespiratory characteristics of flaveria species. Plant Physiol (1991) 1.78
A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med (1995) 1.78
Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J Ind Microbiol Biotechnol (2002) 1.75
Use of antiserum agar plates for serogrouping of meningococci. J Clin Pathol (1977) 1.74
Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care (2008) 1.73
Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol (1997) 1.71